The Epigenetics of Childhood Cancer
News Mar 31, 2016
While childhood cancer is rare (adult malignancies after 20 years are 20-30 times more common in general) it remains a major cause of death by disease in children. 15,700 children are diagnosed with cancer each year in the USA.
Childhood cancer is largely a genetic disease, although its pattern of inheritance is not always clearly defined. It is these genetic mechanisms of susceptibility that are the focus of research for the Cancer Genetics Program at the Hospital for Sick Children (SickKids) in Toronto, Canada.
Research within the Cancer Genetics Program is wide ranging. It includes identifying and studying genes associated with childhood cancer risk; analyzing molecular and cell biology pathways associated with development and progression of cancers; identifying molecules that might represent viable targets for novel drug therapies; and developing practical applications of genetic testing of children and families at risk. It receives more than 190 new referrals each year and to date has consulted on over 1200 families.
Individuals with mutations in the TP53 gene, a condition known as Li-Fraumeni Syndrome (LFS), are one particular focus of the Cancer Genetics Program.
LFS sufferers are predisposed to a wide spectrum of cancers that often develop when they are children. TP53 mutations are also found in women who have developed breast cancer under age 30. Many people with LFS will be diagnosed with cancer two or more times during their lifetime.
Nardin Samuel, an MD/PhD candidate at the Faculty of Medicine, University of Toronto working at the Hospital for Sick Children, Genetics and Genome Biology, Ontario Institute for Cancer Research, is using Qlucore’s Omics Explorer in her PhD work focusing on the epigenetics of LFS cancers.
Epigenetics is the study of the chemical reactions that activate and deactivate specific parts of living organism’s the genome as it develops and the factors that influence these reactions.
It provides insight into regulatory mechanisms that influence gene expression changes, affording the opportunity to study dynamic cellular processes beyond the genome.
Epigenetic analysis of LFS provides a unique avenue to study this syndrome since the causative genetic aberration is well identified, according to Samuel.
A wide range of data
Samuel is studying a range of samples including DNA from patient blood, primary tissue from tumours, and patient cell lines. Cell lines are from lymphoid cells or blood-derived cells or fibroblast cell lines taken from skin biopsies.
Various sequencing approaches are applied to understand how cells are primed to transform and become malignant and in particular, how they can be targeted therapeutically.
“We are doing genetic sequencing, RNA and microRNA analysis, and also experiments in tissue culture in which we are manipulating various genes within the cells lines and analysing their properties,” explains Samuel.
She and her colleagues are dealing with a variety of types and sizes of datasets. Omics Explorer is particularly useful for genome-wide differential methylation analyses, she says.
Excellent visualization tools
“The strength of the Qlucore software is being able to conduct and validate statistical analyses and also produce a variety of visualizations, “explains Samuel.
“It has excellent visualization tools that can make very nice depictions of the data and heat maps.”
Samuel adds that the software is particularly useful for people who don’t have much experience in computational biology or computation in general.
Epigenetics is a growing field in the arena of cancer susceptibility syndromes and approaches to analyzing genome-scale data are essential, she concludes.
HIV-1 replicates in ninja-like ways. The virus slips through the membrane of vital white blood cells. Inside, HIV-1 copies its genes and scavenges parts to build a protective bubble for its copies. Now, supercomputers have helped model a key building block in the HIV-1 protective capsid, which could lead to strategies for potential therapeutic intervention in HIV-1 replication.READ MORE